Financial Performance - Revenue for the year ended December 31, 2023, was RMB 491,373,000, representing a 20.9% increase compared to RMB 406,461,000 in 2022[2] - Gross profit for the year was RMB 389,205,000, up from RMB 313,998,000 in the previous year, reflecting a 24.0% increase[2] - Loss before tax decreased to RMB 752,462,000, a 34.9% improvement from RMB 1,156,344,000 in 2022[2] - Net loss for the year was RMB 746,178,000, down 33.5% from RMB 1,122,042,000 in the prior year[2] - Loss attributable to equity holders of the parent company was RMB 720,876,000, a reduction of 31.8% compared to RMB 1,057,699,000 in 2022[2] - Basic and diluted loss per share improved to RMB (1.65) from RMB (2.42) in the previous year, marking a 31.8% decrease in loss per share[2] - Total revenue for 2023 reached RMB 491,373,000, an increase of 20.9% compared to RMB 406,461,000 in 2022[17] - Revenue from mainland China was RMB 418,699,000, up 18.1% from RMB 354,567,000 in the previous year[15] - The company reported a significant increase in trade payables, which rose to RMB 33,855,000 from RMB 9,126,000, a growth of 270.5%[9] - The company’s total equity decreased to RMB 2,902,224,000 from RMB 3,631,311,000, reflecting a decline of 20.1%[9] Assets and Liabilities - Non-current assets totaled RMB 2,805,647,000, slightly down from RMB 2,813,865,000 in 2022[8] - Cash and cash equivalents decreased significantly to RMB 774,396,000 from RMB 1,879,431,000 in the previous year[8] - Trade receivables were RMB 290,607,000, down from RMB 303,388,000 in 2022[8] - Current liabilities increased significantly to RMB 805,168,000, compared to RMB 492,104,000 in 2022, marking a 63.7% rise[9] - The company's net asset value decreased to RMB 2,902,224,000 from RMB 3,631,311,000, a decline of 20.1% year-over-year[9] - The company’s total non-current liabilities decreased to RMB 689,200,000 from RMB 1,159,420,000, a reduction of 40.5%[9] - The expected revenue to be recognized within one year is RMB 28,842,000, compared to RMB 2,952,000 in the previous year, indicating a significant increase[19] Research and Development - Research and development costs for 2023 are RMB 524,915,000, slightly down from RMB 527,451,000 in 2022[22] - The company is increasing R&D investment in structural heart disease, focusing on innovative solutions to clinical pain points, and aims to maintain its leading position in the valve market[53] - The company has established a product pipeline consisting of 12 innovative devices targeting heart valve diseases, hypertrophic cardiomyopathy, and hypertension[39] - The company is advancing key clinical studies for its Cardiovalve product, with patient enrollment progressing smoothly[38] Product Development and Market Expansion - The first self-developed product, VenusP-Valve, has been approved for clinical research in the US, marking a significant milestone as the first Chinese artificial heart valve product to receive such approval[38] - The company has expanded its TAVR product sales to 10 countries and regions in Asia-Pacific and Latin America, enhancing its international market presence[37] - The VenusA series includes three commercialized TAVR products: VenusA-Valve, VenusA-Plus, and VenusA-Pro, with approvals in 10 countries including China, Asia-Pacific, and Latin America[40] - The company is advancing the VenusP-Valve in the US PROTEUS pivotal clinical trial, having received FDA approval for the IDE application in July 2023[46] - The company plans to continue expanding its international market through innovative product development and proactive commercialization strategies[37] Financial Management and Governance - The company has adopted corporate governance codes and has been providing monthly financial updates to the board since June 2023[103] - All directors and supervisors have confirmed compliance with the securities trading code of conduct for the year ending December 31, 2023[104] - The audit committee has reviewed the financial information for the year ending December 31, 2023, in accordance with the listing rules[106] - The board has proposed not to declare a final dividend for the year ending December 31, 2023[110] Employee and Operational Insights - The company has a total of 865 employees, with 735 located in China and 130 overseas, primarily in the United States and Israel[97] - The company has built a sales team of nearly 220 people, covering over 550 hospitals in China, enhancing its market presence[59] - The company participated in 52 third-party conferences and hosted 35 self-organized meetings in 2023, reaching over 3,900 experts and accumulating 850,000 views[59] Future Outlook - The company provided guidance for the next fiscal year, projecting a revenue growth of 20% and an EBITDA margin of 35%[118] - The company aims to expand in both Chinese and global markets through internal development, mergers, and acquisitions, supported by sufficient bank credit facilities[98] - The company is committed to addressing unmet medical needs and will continue to focus on international sales and clinical research in the structural heart disease treatment field in 2024[101]

Financial Performance - Revenue for the first half of 2023 reached RMB 255.61 million, representing a 21.7% increase compared to RMB 209.97 million in the same period of 2022[9]. - Gross profit for the same period was RMB 201.25 million, up 22.6% from RMB 164.18 million year-on-year[9]. - The company reported a pre-tax loss of RMB 370.34 million, a 50.3% increase from RMB 246.41 million in the previous year[9]. - The net loss for the first half of 2023 was RMB 366.22 million, reflecting a 52.8% increase compared to RMB 239.67 million in the same period of 2022[9]. - The loss attributable to equity holders of the parent company was RMB 350.19 million, a significant increase of 75.2% from RMB 199.93 million year-on-year[9]. - Revenue for the six months ended June 30, 2023, was RMB 255,610 thousand, representing a 21.7% increase from RMB 209,965 thousand in the same period of 2022[130]. - Gross profit for the same period was RMB 201,249 thousand, up from RMB 164,175 thousand, indicating a gross margin improvement[113]. - The net loss for the six months ended June 30, 2023, was RMB 366,215 thousand, compared to a net loss of RMB 239,668 thousand in the same period of 2022, representing a 52.7% increase in losses[113]. Research and Development - The company has invested RMB 294.7 million in R&D for the six months ended June 30, 2023, compared to RMB 220.3 million for the same period in 2022, reflecting a significant increase in R&D expenditure[25]. - Research and development costs increased to RMB 294,715 thousand, compared to RMB 220,316 thousand in the prior year, reflecting a 33.6% rise[113]. - The company is planning to enter two new international markets by the end of 2023, aiming to increase its global footprint[189]. - The company plans to continue its focus on research and development of biological heart valves, which is its primary business segment[124]. Product Development and Pipeline - The company has successfully established a product pipeline consisting of twelve innovative devices targeting heart valve diseases, hypertrophic cardiomyopathy, and hypertension[11]. - The Venus P-Valve product has been approved for commercialization in 30 countries, including Germany, and received FDA IDE approval for clinical research in the United States[10]. - The company is advancing its international clinical studies for innovative products such as Venus-Vitae and Venus-PowerX as planned[10]. - The Cardiovalve product is currently undergoing critical clinical research, with patient enrollment ongoing[10]. - The new generation TAVR product, Venus-Vitae, is set to enter the SMART-ALIGN global pivotal clinical trial phase, utilizing advanced anti-calcification technology[18]. - Venus-PowerX, the first self-expanding dry valve, is in early feasibility studies and will soon enter the IMPACT global pivotal clinical trial phase[19]. - The company aims to develop new materials, bionics, imaging fusion technology, and digital sensing to enhance its product offerings and meet patient needs[10]. Market Expansion and Sales - As of June 30, 2023, sales revenue for the VenusA series products reached RMB 229.8 million, a 16.9% increase from RMB 196.6 million for the same period in 2022[15]. - VenusP-Valve sales revenue for the six months ended June 30, 2023, was RMB 25.2 million, up from RMB 9.1 million for the same period in 2022, representing an increase of RMB 16.1 million[18]. - The company has expanded its sales coverage to 30 countries and regions, including Germany, France, and the UK[29]. - The company is actively pursuing market expansion and product development strategies across multiple jurisdictions[74]. Financial Position and Cash Flow - As of June 30, 2023, the total cash and cash equivalents were RMB 1,453.2 million, a decrease of 22.7% from RMB 1,879.4 million as of December 31, 2022, primarily due to increased R&D and operating expenses[47]. - The total interest-bearing bank borrowings amounted to RMB 778.7 million as of June 30, 2023, compared to RMB 796.0 million as of December 31, 2022, with all borrowings being at floating rates[48]. - The net current assets as of June 30, 2023, were RMB 1,473.0 million, a decrease of 25.5% from RMB 1,976.9 million as of December 31, 2022[49]. - The company experienced a net cash decrease of RMB 437,780,000, with cash and cash equivalents at the end of the period totaling RMB 1,453,165,000, down from RMB 2,121,267,000 a year earlier[123]. Corporate Governance and Compliance - The company has adopted and applied the principles of the corporate governance code, addressing previous compliance issues[106]. - The internal control review conducted by Zhonghui Anda highlighted key areas for operational improvement, which the company is actively addressing[189]. - The company has implemented enhanced internal control measures in response to identified concerns, including revised cash management and internal investigation procedures[104]. - The company has established internal control procedures for handling related party transactions, requiring approval from the general manager for exempt transactions under Listing Rule Chapter 14A[90]. Shareholder Information - The board has proposed not to declare an interim dividend for the six months ending June 30, 2023[60]. - As of June 30, 2023, the total issued share capital of the company is 441,011,443 shares, including 441,010,235 H-shares and 1,208 non-listed foreign shares[66]. - The stock option plan was approved at the extraordinary general meeting on July 12, 2023, allowing for the issuance of up to 44,101,023 H shares, representing approximately 10% of the total issued H shares[82]. Strategic Initiatives - The company plans to conduct international multi-center clinical trials for Venus-Vitae and Venus-PowerX in Europe and other regions to facilitate global market approval[19]. - The company aims to become a leader in the global structural heart disease intervention field, focusing on "international localization and local profitability" as part of its long-term strategy[56]. - The company has completed a strategic acquisition of a smaller competitor, which is projected to enhance its market share by 10%[189].

Financial Performance - Revenue for the six months ended June 30, 2023, was RMB 255,610 thousand, representing a 21.7% increase compared to RMB 209,965 thousand for the same period in 2022[2] - Gross profit for the same period was RMB 201,249 thousand, up 22.6% from RMB 164,175 thousand year-on-year[2] - Loss before tax increased to RMB (370,339) thousand, a 50.3% increase from RMB (246,406) thousand in the previous year[4] - Net loss for the period was RMB (366,215) thousand, reflecting a 52.8% increase compared to RMB (239,668) thousand in 2022[4] - Loss attributable to equity holders of the parent company was RMB (350,188) thousand, a 75.2% increase from RMB (199,933) thousand year-on-year[2] - Basic and diluted loss per share was RMB (0.80), compared to RMB (0.46) in the same period last year, marking a 73.9% increase[5] - The company reported a total comprehensive loss of RMB (310,069) thousand for the period, compared to RMB (164,223) thousand in the previous year[6] Assets and Liabilities - Non-current assets totaled RMB 2,893,350 thousand as of June 30, 2023, compared to RMB 2,813,865 thousand at the end of 2022[7] - Current assets decreased to RMB 2,106,227 thousand from RMB 2,468,970 thousand at the end of 2022[7] - Total liabilities amounted to RMB 1,678,342 thousand, with current liabilities at RMB 633,271 thousand as of June 30, 2023[8] - The group's cash and cash equivalents as of June 30, 2023, were RMB 1,453.2 million, a decrease of 22.7% from RMB 1,879.4 million at the end of 2022[70] - The net value of current assets decreased by 25.5% to RMB 1,473.0 million from RMB 1,976.9 million at the end of 2022[72] Revenue Sources - Revenue from the mainland China market was RMB 233,118,000, up 19.0% from RMB 195,940,000 in the previous year[14] - The company reported a revenue of RMB 248,708 thousand for the six months ended June 30, 2023, compared to RMB 164,808 thousand for the same period in 2022, representing a year-over-year increase of approximately 50.9%[28] - Revenue from the VenusA series products accounted for 89.9% of total revenue, down from 93.7% in the same period last year[55] Costs and Expenses - The cost of goods sold for the six months ended June 30, 2023, was RMB 52,975,000, compared to RMB 44,082,000 for the same period in 2022, reflecting an increase of 20.5%[16] - Sales and distribution expenses rose by 28.0% to RMB 157.9 million, attributed to increased investment in overseas market development[59] - Research and development costs increased by 33.8% to RMB 294.7 million, reflecting higher investment in ongoing R&D projects[60] - Administrative expenses for the same period were RMB 77.9 million, up 42.4% from RMB 54.7 million in the previous year, primarily due to increased professional service fees and office expenses[62] - Financing costs rose to RMB 31.2 million, an increase of 69.5% from RMB 18.4 million, primarily due to fluctuations in floating interest rates[65] Research and Development - The company continues to focus on the research and development of biological heart valves, which is its primary business activity[10] - The company has invested significantly in R&D, with expenses of RMB 294.7 million and RMB 220.3 million for the periods ending June 30, 2023, and June 30, 2022, respectively[47] - The company is investing RMB 200 million in R&D for innovative medical technologies over the next two years[99] Product Development and Market Expansion - The company has successfully established a product pipeline consisting of 12 innovative devices targeting heart valve diseases, hypertrophic cardiomyopathy, and hypertension[32] - The first self-developed product, VenusP-Valve, has been launched in 30 countries in Europe and received FDA IDE approval in July 2023 for critical clinical research in the United States[31] - The company aims to expand its international presence and has successfully entered markets in the UK, Italy, Spain, Denmark, Greece, France, Germany, Poland, and Switzerland[31] - The company plans to focus on unmet medical needs and accelerate global multi-center clinical research while increasing surgical volumes in high-end hospitals domestically[82] Compliance and Governance - The audit committee has reviewed the interim financial results for the six months ending June 30, 2023, and confirmed compliance with relevant accounting standards and regulations[93] - The company has adopted a code of conduct for directors and supervisors regarding securities trading, ensuring compliance with the listing rules[90] - The company has implemented training for directors and senior management regarding listing rule obligations to improve compliance[92] Future Outlook - The company has provided a revenue guidance of RMB 2.5 billion for the second half of 2023, indicating an expected growth of 10%[99] - The company plans to continue expanding in both the Chinese and global markets to maximize shareholder value through internal development, mergers, and acquisitions, supported by sufficient bank credit facilities[79] - The company aims to solidify its leading position in the structural heart disease market by continuously innovating and addressing clinical pain points[46]

Research and Development - In 2022, the company invested RMB 527 million in research and development, accumulating over 630 invention patents across various countries and regions[8]. - The company has built a product pipeline consisting of 12 innovative devices, focusing on addressing clinical pain points in structural heart disease[8]. - The company has established a global R&D innovation platform with three major centers located in Hangzhou, Israel, and California, focusing on breakthrough technologies in heart valve systems[34]. - The breakdown of research and development costs includes employee costs of RMB 148.6 million, raw material costs of RMB 96.3 million, and clinical trial expenses of RMB 55.7 million[50]. - The company has received recognition for its R&D achievements, with a project on new preloaded heart valve systems passing evaluation with an excellent performance rating[35]. - The company is actively involved in research and development of new medical technologies and products[112]. Product Development and Innovation - The VenusP-Valve, the first Class III cardiovascular implant device approved by the EU CE MDR, successfully entered over 20 countries and regions, including the UK, Italy, and Germany[7]. - The company has developed innovative products in the structural heart disease market, including the TAVR products Venus-PowerX and Venus-Vitae, aimed at improving valve durability[33]. - The company is conducting early feasibility studies for Venus-Vitae and Venus-PowerX, with regulatory approvals in Argentina[20]. - The VenusA series TAVR products include VenusA-Valve, VenusA-Plus, and VenusA-Pro, with a total sales revenue of RMB 358.1 million for the year ending December 31, 2022, a decrease of 11.6% from RMB 405.3 million in the previous year[22]. - VenusP-Valve's sales revenue for the year ending December 31, 2022, was RMB 40.9 million, marking a significant increase from zero in the previous year[25]. - The company is advancing confirmatory clinical studies for VenusP-Valve in the US and Japan, having submitted an IDE application to the FDA in March 2023[25]. Financial Performance - The company reported a revenue of RMB 406.461 million for the year ended December 31, 2022, a decrease of 2.5% compared to RMB 415.862 million in 2021[12]. - Gross profit for 2022 was RMB 313.998 million, down from RMB 324.344 million in 2021, reflecting a gross margin of approximately 77.2%[12]. - The company experienced a pre-tax loss of RMB 1.156 billion in 2022, compared to a loss of RMB 377.555 million in 2021, indicating a significant increase in losses[13]. - The net loss attributable to the parent company was RMB 1.058 billion in 2022, compared to RMB 373.636 million in 2021, marking a substantial rise in net losses[14]. - Basic and diluted loss per share for 2022 was RMB 2.42, compared to RMB 0.85 in 2021, reflecting a worsening financial performance[15]. - Other income and gains for the year ended December 31, 2022, were RMB 148.0 million, a decrease of 51.8% from RMB 307.1 million in the previous year[47]. Market Expansion and Sales Strategy - The company plans to establish global operational centers to facilitate the entry of products into various markets through localized branding[7]. - The company plans to expand its international sales regions for VenusP-Valve, targeting over 50 countries and regions for market entry in 2023[17]. - The company is actively expanding its global market presence, with product registrations and market access capabilities improving in Southeast Asia, Central Asia, and Latin America[40]. - The company aims to enhance its clinical research capabilities and product registration processes to cover more countries and markets[17]. - The company is focusing on the development of new interventional therapies for the mitral and tricuspid valves, which are expected to be key growth points in the future[33]. - The company is targeting new growth areas in the treatment of congenital heart disease with its VenusP-Valve product, which has been approved for sale in Europe and China[33]. Acquisitions and Collaborations - The acquisition of Israeli innovative medical device company Cardiovalve was completed, enhancing the company's presence in the two and three-leaf valve intervention field[7]. - The company completed the acquisition of Cardiovalve for a total consideration of approximately $266 million on January 25, 2022, making Cardiovalve a wholly-owned subsidiary[66]. - The company established the Venus Medtech International Valve Innovation Center in Israel to promote collaboration between domestic and international R&D teams[7]. - Cardiovalve's products are in early feasibility and confirmatory clinical trial stages, with a 55 mm valve ring design suitable for approximately 95% of patients[28]. Regulatory and Compliance - Regulatory approvals are critical for the commercialization of the company's products, and delays could severely impact revenue generation capabilities[80]. - The company has successfully passed remote and on-site audits for its quality management system, maintaining high standards in product quality from R&D to market[38]. - The company complies with the listing rules requiring at least three independent non-executive directors, with one possessing appropriate professional qualifications[195]. - The company has maintained compliance with all relevant laws and regulations during the reporting period[115]. Risk Management - The company recognizes the importance of risk management, particularly in the context of the evolving regulatory environment and competition in the medical device market[88]. - The company has adopted a comprehensive risk management policy to identify, assess, and monitor key risks related to its strategic objectives[88]. - The Chief Financial Officer is responsible for formulating and updating risk management policies and ensuring the implementation of risk management measures across departments[90]. - The company faces significant risks related to product development, regulatory compliance, and operational challenges that could impact financial performance[79]. Corporate Governance - The company emphasizes corporate governance and compliance, with board members holding significant qualifications in law and finance[105]. - The board of directors consists of seven members, including three executive directors and three independent non-executive directors[195]. - The company held five board meetings during the year ending December 31, 2022, to review and approve annual performance and interim results[198]. - The independent non-executive directors provide diverse business experience and professional knowledge to enhance board effectiveness[197]. Employee and Organizational Development - The company has a total of 1,028 employees, with 871 based in China and 157 overseas, primarily in the United States and Israel[71]. - The company is committed to providing competitive compensation and benefits to employees, including ongoing education and training programs[72]. - The company invests in continuous education and training programs for employees to enhance their skills and knowledge levels[116]. - The management team includes experienced professionals with extensive backgrounds in medical device regulation and compliance, enhancing the company's regulatory affairs capabilities[96].

Financial Performance - Total revenue for the year ended December 31, 2022, was RMB 406,461,000, a decrease of 2.3% compared to RMB 415,862,000 in 2021[2] - Gross profit for the same period was RMB 313,998,000, down 3.2% from RMB 324,344,000 in the previous year[2] - The company reported a loss before tax of RMB (1,156,344,000), an increase of 206.3% from RMB (377,555,000) in 2021[2] - Net loss for the year was RMB (1,122,042,000), representing a 202.1% increase compared to RMB (371,394,000) in the prior year[2] - Basic and diluted loss per share was RMB (2.42), compared to RMB (0.85) in 2021, reflecting an increase of 184.7%[6] - The company recorded other income and gains of RMB 147,988,000, down from RMB 307,147,000 in the previous year[4] - The foreign exchange difference from overseas operations resulted in a gain of RMB 118,952,000, compared to a loss of RMB (17,671,000) in 2021[4] - The company reported a pre-tax loss of RMB 1,057,699 thousand in 2022, compared to a loss of RMB 373,636 thousand in 2021, indicating a substantial increase in losses[35] - Other income increased significantly to RMB 66,261 thousand in 2022 from RMB 58,085 thousand in 2021, primarily due to government subsidies rising to RMB 31,128 thousand from RMB 6,687 thousand[22] Research and Development - Research and development expenses rose significantly to RMB (527,451,000) from RMB (258,336,000), indicating a focus on innovation[4] - R&D expenses for the years ended December 31, 2021, and December 31, 2022, were RMB 258.3 million and RMB 527.5 million, respectively, indicating a significant increase in investment[63] - The company is focused on research and development to advance its product offerings in the cardiovascular space[117] - The company aims to develop new materials, biomimetic technologies, imaging fusion technologies, and digital sensing to enhance its product offerings[46] Assets and Liabilities - Non-current assets increased to RMB 2,813,865,000 from RMB 1,669,835,000, driven by investments in goodwill and other intangible assets[7] - Cash and cash equivalents decreased to RMB 1,879,431,000 from RMB 2,955,212,000, indicating a reduction in liquidity[7] - Total current liabilities increased significantly to RMB 492,104 thousand in 2022 from RMB 208,534 thousand in 2021, representing a growth of 136.0%[8] - Non-current liabilities rose sharply to RMB 1,159,420 thousand in 2022 from RMB 269,079 thousand in 2021, marking an increase of 331.0%[8] - The net asset value decreased to RMB 3,631,311 thousand in 2022 from RMB 4,631,844 thousand in 2021, a decline of 21.6%[8] Revenue Breakdown - Revenue from mainland China was RMB 354,567 thousand in 2022, down from RMB 405,346 thousand in 2021, a decrease of 12.5%[16] - Revenue from other regions increased significantly to RMB 51,894 thousand in 2022 from RMB 10,516 thousand in 2021, a growth of 394.0%[16] - Total revenue from customer contracts for medical equipment in 2022 was RMB 406,461 thousand, a decrease of 2.0% from RMB 415,862 thousand in 2021[19] - Sales from the VenusA series products accounted for 88.1% of total revenue, down from 97.4% in the previous year[73] - Overseas revenue reached RMB 51.2 million, representing 12.6% of total revenue, driven by the approval of VenusP-Valve in the EU[68] Product Development and Clinical Trials - The company has established a product pipeline consisting of 12 innovative devices targeting heart valve diseases, hypertrophic cardiomyopathy, and hypertension[47] - The company is conducting clinical trials for TAVR products Venus-Vitae and Venus-PowerX, with Cardiovalve products also undergoing clinical trials for TMVR and TTVR applications[49] - The company is developing the next-generation TAVR products, Venus-PowerX and Venus-Vitae, which are currently in early feasibility studies[54][55] - The VenusP-Valve demonstrated a 100% procedural success rate and a 0% mortality rate in a three-year follow-up study presented at the CSI conference[52] - The company is advancing clinical studies for VenusP-Valve in the US and Japan, having submitted an IDE application to the FDA in March 2023[53] Strategic Goals and Market Expansion - The company has a long-term strategic goal to become a leader in the field of structural heart disease intervention, focusing on effective treatment solutions for significant diseases[46] - The company plans to continue expanding in both domestic and global markets, utilizing various financing channels to support capital expenditures[99] - The company aims to complete international sales of VenusP-Valve in over 50 countries and regions this year, targeting strong and sustainable sales growth[101] - The company is actively participating in international cardiology conferences and industry exhibitions to enhance global brand recognition[101] Financial Management and Capital Expenditure - The group's cash and cash equivalents decreased by 36.4% to RMB 18,794 million as of December 31, 2022, down from RMB 29,552 million, mainly due to increased R&D and operating expenses as well as investment expenditures[89] - Financing costs increased significantly to RMB 446 million for the year ended December 31, 2022, from RMB 19 million in the previous year, primarily due to increased interest expenses on bank borrowings[85] - Total capital expenditure for the year ended December 31, 2022, was approximately RMB 1,090.4 million, allocated to various investments and asset purchases[94] Corporate Governance and Compliance - The audit committee, consisting of three independent non-executive directors, confirmed that the financial performance for the year ended December 31, 2022, complies with relevant accounting standards[110] - The company is committed to adhering to international quality standards, including GMP and FDA regulations, to ensure product safety and efficacy[116]

Financial Performance - Revenue for the six months ended June 30, 2022, was RMB 209,965,000, a decrease of 12.2% compared to RMB 239,269,000 for the same period in 2021[8]. - Gross profit for the same period was RMB 164,175,000, down 12.7% from RMB 188,088,000 year-on-year[8]. - Loss before tax increased to RMB 246,406,000, representing a 110.2% increase from RMB 117,211,000 in the previous year[8]. - The net loss for the period was RMB 239,668,000, up 104.5% from RMB 117,215,000 in the prior year[8]. - The loss attributable to equity holders of the parent was RMB 199,933,000, a 76.8% increase compared to RMB 113,063,000 in the same period last year[8]. - As of June 30, 2022, the company's total revenue was RMB 210.0 million, a decrease of 12.2% compared to RMB 239.3 million for the same period in 2021[49]. - Revenue from VenusA-Valve and VenusA-Plus accounted for 93.7% of total revenue, down from 98.1% in the previous year[49]. - The sales cost for the first half of 2022 was RMB 45.8 million, a decrease of 10.5% from RMB 51.2 million in the same period of 2021[52]. - Gross profit decreased by 12.7% to RMB 164.2 million, with a gross margin of 78.2%, compared to 78.6% in the previous year[53]. - Other income and gains increased by 78.8% to RMB 62.4 million, primarily due to government subsidies and foreign exchange gains[54]. Product Development and Innovation - The company has successfully established a product pipeline consisting of 14 innovative devices, including three marketed TAVR products[10]. - VenusA-Pro has been approved for market launch in China, further enriching the TAVR product line[9]. - The company is focusing on the development of new materials, biomimetics, imaging integration technology, and digital transmission to enhance its product offerings[9]. - Eight clinical trials are currently underway globally, showcasing the company's innovation and R&D capabilities[9]. - The company aims to expand its international commercialization efforts and enhance its market competitiveness[9]. - VenusP-Valve received CE MDR certification on April 8, 2022, and was approved for sale in Europe, marking it as the first self-expanding TPVR product approved under the new CE MDR regulations[17]. - VenusP-Valve was also approved for sale in China in July 2022, filling a clinical need for severe pulmonary valve regurgitation patients[17]. - The VenusA-Plus product, launched in November 2020, features a retrievable and repositionable design, significantly reducing procedural difficulty and shortening the learning curve for operators[12]. - The company is actively expanding its product pipeline, with several products in various stages of clinical trials and regulatory approvals[12]. - VenusP-Valve achieved a 100% surgical success rate with 64 patients, and both mortality and re-intervention rates were 0%[20]. Market Expansion and Sales - TAVR product sales revenue for the six months ending June 30, 2022, was RMB 196.6 million, a decrease of 16.2% compared to RMB 234.7 million for the same period in 2021[15]. - As of June 30, 2022, overseas sales revenue for VenusP-Valve reached RMB 9.1 million, compared to zero in the same period of 2021[20]. - The company continues to expand its overseas market presence, with a focus on Southeast Asia, Central Asia, and Latin America, enhancing brand influence through local partnerships[45]. - The company plans to continue expanding in China and globally to maximize shareholder value through internal development, mergers, and acquisitions[78]. - The company aims to maintain stable gross profit margins while pursuing high-quality growth and addressing unmet medical needs in the domestic market[80]. Research and Development - R&D expenses increased from RMB 104.3 million in the first half of 2021 to RMB 220.3 million in the first half of 2022, representing a growth of 110%[37]. - The company holds a total of 786 patents and patent applications as of June 30, 2022, including 319 granted invention patents[39]. - The company established a global cardiac valve innovation center in Israel to enhance its global innovation system and product layout[36]. - The company is focusing on innovative products in structural heart disease, including the latest generation TAVR products PowerX and Vitae, aimed at addressing valve durability issues[35]. - The company has ongoing research and development for multiple products, including TMVR and TTVR technologies[116]. Financial Position and Liabilities - The total interest-bearing bank borrowings amounted to RMB 924.7 million as of June 30, 2022, compared to RMB 4.9 million at the end of 2021, resulting in a capital debt ratio of 21.8%, up 1,353.3% from 1.5%[68]. - The group's net current assets were RMB 2,253.2 million, a decrease of 30.3% from RMB 3,231.1 million as of December 31, 2021[69]. - The group completed the acquisition of Cardiovalve for a consideration of USD 266 million on January 25, 2022, making Cardiovalve a wholly-owned subsidiary[72]. - The group reported a pre-tax loss of RMB 199,933 thousand for the six months ended June 30, 2022, compared to a loss of RMB 113,063 thousand in the same period of 2021[161]. - The total liabilities increased to RMB 1,865,736 thousand from RMB 418,613 thousand, indicating a rise in financial obligations[133]. Corporate Governance and Compliance - The company has adopted and applied the corporate governance code as per the listing rules, and has complied with all mandatory provisions during the reporting period[8]. - The audit committee reviewed and discussed the financial performance for the six months ending June 30, 2022, confirming compliance with relevant accounting standards[9]. - The company is committed to ensuring compliance with corporate governance codes and has disclosed relevant details regarding the re-election of directors[107]. - There were no significant litigation or arbitration matters during the reporting period[10]. - The company has not reported any changes in the information of directors and supervisors that require disclosure under the listing rules since the last annual report[12].

Financial Performance - In 2021, Venus Medtech reported revenue of RMB 415.862 million, a significant increase of 50.7% compared to RMB 276.047 million in 2020[21]. - The gross profit for 2021 was RMB 324.344 million, up 42.7% from RMB 227.280 million in 2020[21]. - The company experienced a pre-tax loss of RMB 377.555 million in 2021, which is an increase in loss compared to RMB 185.843 million in 2020[21]. - VenusA-Valve and VenusA-Plus sales revenue reached RMB 405.3 million for the year ending December 31, 2021, an increase of 49% compared to RMB 272.0 million for the year ending December 31, 2020[30]. - Other income and gains for the year ended December 31, 2021, amounted to RMB 307.1 million, an increase of 159.5% compared to RMB 118.2 million for the year ended December 31, 2020[65]. - Sales and distribution expenses for the year ended December 31, 2021, were RMB 216.1 million, up 60.5% from RMB 134.6 million for the year ended December 31, 2020[66]. - Research and development costs for the year ended December 31, 2021, were RMB 258.3 million, a 54.4% increase from RMB 167.3 million for the year ended December 31, 2020[67]. - Administrative expenses for the year ended December 31, 2021, were RMB 128.6 million, up 23.5% from RMB 104.1 million for the year ended December 31, 2020[70]. - The adjusted net loss for the year ended December 31, 2021, was RMB 371.4 million, compared to an adjusted net loss of RMB 173.9 million for the year ended December 31, 2020[77]. Product Development and Innovation - The company has established a product pipeline consisting of 14 innovative devices, including two marketed TAVR products, VenusA-Valve and VenusA-Plus[25]. - VenusA-Valve, the first TAVR device approved by NMPA in China, has been implanted in over 9,000 cases, demonstrating its safety and efficacy[28]. - VenusA-Plus, launched in November 2020, is the first recoverable TAVR product in China, enhancing procedural ease and reducing learning curves for surgeons[28]. - The company plans to focus on developing new materials, biomimetic technologies, imaging integration, and digital sensing to expand its product offerings[24]. - The company has developed proprietary anti-calcification processing technology to enhance the durability of its TAVR products[35]. - The company is advancing its clinical trials for VenusA-Pro and VenusP-Valve, with NMPA approval pending for both products[27]. - VenusP-Valve is expected to meet the needs of over 85% of patients without the need for stents or balloon dilation[32]. - The company has initiated a training program for engineers between China and Israel to foster innovation talent for long-term development[47]. Market Expansion and Acquisitions - Venus Medtech completed the acquisition of Cardiovalve on January 26, 2022, enhancing its market presence in the mitral and tricuspid valve disease segments[9]. - The company aims to expand its international strategy, with the commercialization of VenusP-Valve in the EU in 2022[9]. - The company has successfully registered VenusA-Valve in Southeast Asia and Latin America, including Thailand, Colombia, and Brazil[28]. - The company aims to enhance its market presence through strategic acquisitions and partnerships with leading technology firms[24]. - Cardiovalve acquisition completed for $266 million, enhancing the company's product portfolio in treating mitral and tricuspid regurgitation[37]. - The company plans to accelerate clinical development and registration of Cardiovalve in the Chinese market following the acquisition[37]. Financial Position and Assets - Total non-current assets amounted to 1,669,835 million, while total current assets reached 3,439,622 million, indicating a strong asset base[22]. - The total liabilities were 208,534 million for current liabilities and 269,079 million for non-current liabilities, reflecting a manageable debt level[22]. - The total equity of the company stands at 4,631,844 million, indicating a solid financial position for future growth[22]. - As of December 31, 2021, the group's cash and cash equivalents amounted to RMB 2,955.2 million, representing a 9.1% increase from RMB 2,708.2 million as of December 31, 2020[81]. - The group's net current assets as of December 31, 2021, were RMB 3,231.1 million, an increase of 9.3% from RMB 2,954.9 million as of December 31, 2020[83]. Risks and Challenges - The company acknowledges the uncertainty in successfully developing and marketing its products, including Cardiovalve and TriGUARD3[38][41]. - The company has incurred net losses since its establishment and may continue to do so in the foreseeable future, posing a high risk for potential investors[102]. - Future growth is largely dependent on the success of the company's research and development products, with significant delays in clinical development or regulatory approval potentially causing substantial business harm[102]. - The company faces strict regulatory oversight in all critical aspects of product research, development, and commercialization, with delays in obtaining necessary approvals severely impacting revenue generation capabilities[103]. - The complexity of product manufacturing and strict quality control measures mean that any issues with suppliers or logistics could adversely affect the business[106]. - The company may struggle to protect its intellectual property, which is crucial for maintaining competitive advantages in the market[106]. - The company's reputation and profitability could be significantly affected if its products are associated with serious adverse events[105]. Corporate Governance and Management - The company emphasizes the importance of independent directors in corporate governance and strategic decision-making[134]. - The management team has extensive industry experience, with key executives having over 18 years of experience in the medical device sector[120]. - The board includes members with diverse backgrounds in law, finance, and healthcare, enhancing its strategic capabilities[134]. - The company has established collaborations for clinical development, but there is a risk of not realizing the expected benefits from these partnerships[108]. - The company actively participates in major cardiology conferences in China to provide training on TAVR and TPVR procedures, showcasing product innovations[151]. Research and Development - Research and development expenses for the years ended December 31, 2020, and December 31, 2021, were RMB 167.3 million and RMB 258.3 million, respectively, indicating a year-over-year increase of 54.3%[48]. - The company’s R&D centers are located in Hangzhou, Israel, and California, emphasizing its commitment to global R&D innovation[46]. - The company is focused on the development and commercialization of TMVR and TPVR products, including VenusA-Valve and VenusP-Valve[122]. Shareholder Information - The total issued share capital of the company as of December 31, 2021, is 441,011,443 shares, including 441,010,235 H shares and 1,208 non-listed foreign shares[179]. - The company has a significant presence of institutional investors, with multiple entities holding substantial stakes in H shares[176]. - The company’s major shareholders include both domestic and international investment firms, indicating a diversified ownership structure[176]. - The company reported a total issued share capital of 441,011,443 shares as of December 31, 2021, including 441,010,235 H shares and 1,208 non-listed foreign shares[184].

Financial Performance - Revenue for the six months ended June 30, 2021, was RMB 239.27 million, representing a 134% increase compared to RMB 102.05 million for the same period in 2020[8]. - Gross profit for the same period was RMB 188.09 million, up 121% from RMB 85.09 million year-on-year[8]. - Loss before tax increased to RMB 117.21 million, a 169% increase from RMB 43.53 million in the previous year[8]. - The net loss for the period was RMB 117.22 million, compared to RMB 43.54 million in the same period last year, marking a 169% increase[8]. - The company reported a basic and diluted loss per share of RMB 0.26, compared to RMB 0.11 in the same period last year, reflecting a 136% increase in loss per share[8]. - The group reported a loss attributable to ordinary shareholders of RMB 113,063,000 for the six months ended June 30, 2021, compared to a loss of RMB 43,524,000 for the same period in 2020[136]. - The company incurred a net loss of RMB 117.22 million for the six months ended June 30, 2021, compared to a net loss of RMB 43.54 million in the prior year, reflecting a deterioration in profitability[105]. - The company's accumulated losses reached RMB 608,258,000 as of June 30, 2021, compared to RMB 564,734,000 at the end of 2020[110]. Research and Development - The company has a pipeline of ten self-developed medical devices, including two marketed TAVR products and several in various stages of clinical trials and registration[10]. - The company aims to focus on new materials, bionics, imaging fusion technology, and digital sensing in future product development[9]. - Research and development expenses were RMB 67.6 million and RMB 104.3 million for the six months ending June 30, 2020, and June 30, 2021, respectively, indicating a significant increase in investment[27]. - The company is advancing its R&D efforts, with plans to enter clinical trials for new products such as the Vitae balloon-expandable valve and the PowerX self-expanding valve in the second half of 2021 and the first half of 2022, respectively[65]. - The company is developing multiple TTVR devices for tricuspid regurgitation (TR), with several in preclinical or early clinical trial stages, expanding treatment options for high-risk patients[21]. - The company is focused on expanding its market presence through innovative minimally invasive procedures like TAVR and TMVR[170]. - The ongoing development of the TPVR technology reflects the company's commitment to addressing unmet medical needs in cardiac care[170]. Product Development and Market Expansion - The VenusA-Valve and VenusA-Plus TAVR products have received approvals in multiple countries, including Colombia, Brazil, and Thailand[12]. - The company is preparing for the registration phase of the VenusA-Pro TAVR product and is entering first-in-man (FIM) trials for Venus PowerX and Venus Vitae[12]. - The company is in the pre-clinical stage for Venus PowerX Valve, a third-generation self-expanding TAVR device, expected to enter clinical trials in China in the first half of 2022[19]. - Venus Vitae Valve, another third-generation TAVR device, has completed animal trials and is anticipated to enter clinical trials in the second half of 2021[19]. - The company has registered VenusA-Valve in Southeast Asia and Latin America, including countries like the Philippines, Thailand, Colombia, and Brazil[13]. - The market outlook for TAVR treatment is promising, with an expected increase in AS patients receiving TAVR therapy due to expanded indications[14]. - The company plans to launch the VenusP-Valve product in the EU, with established distribution channels in Germany, Belgium, the Netherlands, Canada, the UK, and Ireland[68]. Sales and Revenue - The sales revenue for VenusA-Valve and VenusA-Plus for the six months ending June 30, 2021, was RMB 234.7 million, an increase of 131.0% compared to RMB 101.6 million for the same period in 2020[17]. - Sales from VenusA-Valve and VenusA-Plus accounted for 98.1% of total revenue, with VenusA-Valve generating RMB 234.7 million and VenusA-Plus contributing significantly to growth[37]. - As of June 30, 2021, the total surgical implant volume for VenusA-Valve and VenusA-Plus reached approximately 1,900 units, covering around 300 hospitals, with VenusA-Plus accounting for over 20% of the surgeries[15]. - The company has conducted over 6,000 surgeries with its first-generation TAVR product, VenusA-Valve, and increased its hospital coverage to 300, adding 51 hospitals compared to the end of 2020[62]. - The sales of VenusA-Plus are showing rapid growth, with one-year clinical follow-up data indicating a low incidence of complications[62]. Financial Position and Assets - The group's cash and cash equivalents increased by 32.2% to RMB 3,579.8 million as of June 30, 2021, from RMB 2,708.2 million as of December 31, 2020[51]. - The group's net current assets increased by 31.4% to RMB 3,882.4 million as of June 30, 2021, from RMB 2,954.9 million as of December 31, 2020[53]. - The total non-current assets as of June 30, 2021, amounted to RMB 1,089.85 million, an increase from RMB 957.79 million at the end of 2020[106]. - The company reported a net cash increase of RMB 886,001,000 for the six months ended June 30, 2021, compared to a net cash decrease of RMB 451,238,000 in the same period of 2020[doc id='113']. - The total capital expenditure for the six months ended June 30, 2021, was approximately RMB 165.3 million, allocated to investments in an associate, financial assets, property, plant and equipment, equity investments, and intangible assets[56]. Corporate Governance and Compliance - The company has adopted and applied the corporate governance code as per the listing rules, complying with all mandatory provisions during the reporting period[81]. - The audit committee reviewed the interim financial performance for the six months ending June 30, 2021, ensuring compliance with relevant accounting standards[84]. - There were no significant litigation or arbitration matters during the reporting period[85]. - The company has not granted any rights to directors or supervisors to benefit from purchasing shares or debt securities[75]. Strategic Partnerships and Collaborations - The company established a joint venture with Healium Medical Ltd for the development of a new generation renal denervation (RDN) device, enhancing treatment for uncontrolled hypertension[25]. - The company has entered into collaborations to introduce innovative technologies, including a partnership with Endoluminal Sciences for active anti-paravalvular leak technology[30]. - The company is exploring strategic partnerships to enhance its product development and market reach[171]. Future Outlook - The company plans to continue expanding in both the Chinese and global markets through internal development, mergers, and acquisitions, supported by various financing channels including internal funds and bank loans[60]. - Future guidance indicates a strong focus on expanding the product pipeline and increasing market penetration in the coming years[171].

Financial Performance - The company's total revenue for the year reached RMB 276 million, representing an 18.3% year-over-year growth, with a 38.3% increase in the second half of the year[5]. - In 2020, the company reported revenue of RMB 276,047,000, an increase of 18.3% from RMB 233,272,000 in 2019[13]. - For the fiscal year ending December 31, 2020, the company's total revenue was RMB 276.0 million, an increase of 18.3% from RMB 233.3 million in the previous year[53]. - VenusA-Valve sales revenue reached RMB 272.0 million for the year ended December 31, 2020, an increase of 17.2% compared to RMB 232.1 million for the year ended December 31, 2019[25]. - The gross profit for 2020 was RMB 227,280,000, representing a gross margin of approximately 82.2%[13]. - The group's gross profit increased by 16.7% from RMB 194.7 million in the year ended December 31, 2019, to RMB 227.3 million in the year ended December 31, 2020[57]. - Other income and gains rose significantly by 667.5% to RMB 118.2 million for the year ended December 31, 2020, compared to RMB 15.4 million for the year ended December 31, 2019, mainly due to increased government project subsidies and higher interest income[58]. - The adjusted net loss for the year ended December 31, 2020, was RMB 173.868 million, a decrease from RMB 235.473 million in 2019, representing a 26.2% improvement[69]. Product Development and Innovation - The second-generation artificial valve system, VenusA-Plus, was approved for market launch, becoming China's first artificial valve system with a recapturable feature, enhancing surgical safety[6]. - The self-expanding pulmonary valve product, VenusP-Valve, is in the final stage of CE certification and is preparing for clinical registration in the U.S.[10]. - The company has two TAVR products currently on the market and several others in various stages of development, including one product in the pre-registration phase[19]. - The company is conducting preclinical studies for VenusA-Pro Valve, which aims to improve control over valve deployment and recapturability[33]. - The design phase for Venus PowerX Valve is currently underway, focusing on self-expanding technology and improved safety and efficacy for patients[34]. - The company is also developing Venus Vitae Valve, which utilizes balloon-expandable technology for treating severe aortic stenosis[37]. - The company plans to commercialize VenusP-Valve and other products in China, leveraging its experience from the successful commercialization of VenusA-Valve[93]. - The company plans to expand its pipeline in structural heart disease, covering all four heart valves and investing in technological innovation to enhance competitiveness[99]. Market Expansion and Strategic Partnerships - The company aims to enhance its international presence, with products and sales networks expanding rapidly across global markets[10]. - The company is actively seeking strategic partners globally, collaborating with Opus Medical Therapies, LLC and Pi-Cardia Ltd. for innovative device development[9]. - The company plans to expand its market presence in China and globally through internal development, mergers, and acquisitions, supported by sufficient bank credit facilities[87]. - The company intends to expand its market share in North America, the EU, and emerging markets, benefiting from higher healthcare spending levels in these regions[96]. - The company plans to leverage existing brands like TriGUARD3 to enter the US and EU markets, with clinical trials and registration applications ongoing[97]. Operational Efficiency and Cost Management - The company has established a strong R&D platform with capabilities in development, production, and commercialization of catheter-based heart valve products[47]. - The internal sales team focuses on academic marketing to promote TAVR products and increase market penetration in China[51]. - Sales and distribution expenses increased by 8.0% to RMB 134.6 million for the year ended December 31, 2020, from RMB 124.6 million in the previous year, aligning with the increase in sales revenue[59]. - Administrative expenses decreased by 47.3% to RMB 104.1 million for the year ended December 31, 2020, compared to RMB 197.6 million in the previous year, primarily due to the absence of significant prior year expenses related to employee incentives and listing fees[62]. - The company aims to enhance its corporate governance and compliance measures, ensuring alignment with industry standards and regulations[151]. Risk Management and Compliance - The company emphasizes the importance of risk management and internal control, with the audit committee overseeing significant risks and management's handling of these risks[121]. - The company faces significant risks related to product development, regulatory approvals, and potential delays in commercialization[101]. - Regulatory approvals are critical for the commercialization of in-development products, and delays could severely impact revenue generation capabilities[104]. - The company is required to pay taxes on global income in China, which may affect dividend payments and shareholder returns[117]. - The company has established a dedicated intellectual property department to assist in the registration and analysis of intellectual property rights[126]. Employee and Stakeholder Engagement - The company provides various incentives and benefits to attract and retain quality employees, including competitive compensation and training programs[185]. - The company has a commitment to continuous education and training for its employees to enhance their skills and knowledge[185]. - The company recognizes the importance of maintaining strong relationships with various stakeholders, including employees and business partners, for sustainable development[185].

日 信明医疗 杭州啓明醫療器械股份有限公司 Venus Medtech (Hangzhou) Inc. (於中華人民共和國註冊成立的股份有限公司) 股份代號：2500 2020 中期報告 | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------|-------|----------------------------------|-------|-------|-------| | | | | | 目錄 | | | | | | | | | | | | | | | | | | | | | | | | | | 2 | 公司資料 | | | | | | | | 3 | 財 務 摘 要 | | | | | | | | 4 | 管理層討論與分析 | | | | | | | | 23 | 企業管治 及 其他資料 | | | | | | | | 37 | 中期簡明綜合損益及其他全面收益表 | | | | | | | | 39 | 中期簡明綜合財務狀況表 | | | | | | | | 41 | 中期簡明綜合權益變動表 | | | | ...